文献速递甲状腺疾病

靶向癌相关成纤维细胞B7-H3的纳米系统抑制未分化甲状腺癌进展

Targeting B7-H3 in Cancer-Associated Fibroblasts Using Nanosystems Suppresses Anaplastic Thyroid Carcinoma Progression.
PubMed 文献 · Thyroid · 2025-09-03

本研究开发了靶向PDGFR-β阳性癌相关成纤维细胞(CAFs)的纳米颗粒,递送B7-H3 siRNA以敲低B7-H3表达。体外实验显示敲低B7-H3可抑制CAFs增殖并改变其分泌的细胞因子,进而减少未分化甲状腺癌(ATC)细胞的增殖、侵袭和迁移;小鼠皮下瘤模型局部注射该纳米颗粒可缩小肿瘤体积并下调侵袭、免疫逃逸及化疗耐药相关标志物。结果表明B7-H3是ATC的潜在治疗靶点。

要点

  • 靶向PDGFR-β阳性CAFs的纳米颗粒可有效递送B7-H3 siRNA并实现靶向敲低。
  • 敲低CAFs中的B7-H3可抑制CAFs增殖并改变其细胞因子分泌谱。
  • 局部注射该纳米颗粒可缩小小鼠ATC皮下瘤体积并下调多种恶性标志物。

核心结论

  • 靶向CAFs中B7-H3的纳米系统可抑制ATC的增殖、侵袭和迁移,B7-H3是ATC的有前景的治疗靶点。

研究设计与样本

  • 研究构建了PDGFR-β靶向多肽修饰的pBAE(T-pBAE)/siB7-H3纳米颗粒,用于靶向PDGFR-β阳性CAFs并敲低B7-H3。
  • 研究评估了纳米颗粒的靶向效率和基因沉默效果,以及B7-H3对CAFs驱动ATC进展的功能贡献。
  • 研究在 mice ATC 皮下肿瘤模型中局部注射纳米颗粒并观察肿瘤体积及标志物表达变化。

主要发现

  • T-pBAE/siB7-H3纳米颗粒可被CAFs高效内化,实现B7-H3表达的靶向敲低。
  • 沉默B7-H3显著抑制细胞分裂周期27(cell division cycle 27)及其他细胞周期相关基因表达,从而抑制CAFs增殖。
  • CAFs分泌的细胞因子(如CCL1和CCL4)发生改变,通过调节ATC细胞上的细胞因子受体激活,减少ATC细胞增殖、侵袭和迁移。
  • 小鼠ATC皮下肿瘤模型中局部注射T-pBAE/siB7-H3纳米颗粒可缩小肿瘤体积。
  • 肿瘤组织中侵袭增殖相关标志物(PDGFR-β、Ki-67、CD31)、免疫逃逸相关标志物CD163和化疗耐药相关标志物ATP结合盒亚家族G成员2表达显著下调。

临床怎么用

  • 本研究为临床前探索,提示靶向CAFs中B7-H3的纳米递送策略可能成为ATC的潜在治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Anaplastic thyroid carcinoma (ATC) represents a rare yet highly malignant histotype of thyroid cancer. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor cell invasion, migration, and angiogenesis and present a potential target for cancer treatment. We aimed to investigate the effects of modulating specific subsets of CAFs on the proliferation, invasion, and migration of ATC. Methods: We developed nanosystems, platelet-derived growth factor receptor (PDGFR-β) targeted-polypeptide-modified poly (β-amino ester) (pBAE) (T-pBAE)/siB7-H3 nanoparticles (NPs), targeting PDGFR-β+ CAFs and featuring B7-H3 knockdown. We evaluated both the targeting efficacy and gene silencing performance of T-pBAE/siB7-H3 NPs, as well as the functional contribution of B7-H3 to CAFs-driven ATC progression. Results: T-pBAE/siB7-H3 NPs were efficiently internalized by CAFs, achieving targeted knockdown of B7-H3 expression. Silencing B7-H3 significantly suppressed the expression of cell division cycle 27 and other cell cycle-related genes, thereby inhibiting CAFs' proliferation. Consequently, CAFs-secreted cytokines (e.g., CCL1 and CCL4) were altered. Through modulation of cytokine receptor activation on ATC cells, this process reduced ATC cell proliferation, invasion, and migration. In mice ATC subcutaneous tumor models, local injection of T-pBAE/siB7-H3 NPs reduced tumor volume. Moreover, the expression of invasive proliferation-related markers (PDGFR-β, Ki-67, CD31), immune evasion-related marker CD163, and chemoresistance-related marker ATP-binding cassette subfamily G member 2 was remarkably downregulated in tumor tissues. Conclusion: This study demonstrates that PDGFR-β polypeptide-modified pBAE could successfully deliver B7-H3 siRNA to CAFs. After knockdown of B7-H3 within CAFs, ATC proliferation, invasion, and migration were inhibited. Overall, our findings revealed that B7-H3 can be a promising therapeutic target for ATC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Chen T, Li X, Hong D, et al. Targeting B7-H3 in Cancer-Associated Fibroblasts Using Nanosystems Suppresses Anaplastic Thyroid Carcinoma Progression. Thyroid. 2025. PMID: 40897519. doi:10.1177/10507256251372644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。